Author

T. Spicer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 4 Assay:bulk RNA-seq· 2 Organism:human· 2 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

L. Scampavia· 4 shared Y. Otsuka· 2 shared A. Biankin· 1 shared B. Sridharan· 1 shared C. Rood· 1 shared C. V. Leiton· 1 shared C.-H. Pan· 1 shared C.-i. Hwang· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

L. Scampavia

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A new vulnerability to BET inhibition due to enhanced autophagy in BRCA2 deficient pancreatic cancer

E. Lee, S. Archasappawat, K. Ji, J. Pena, V. Fernandez-Vega, R. Gangaraju, N. S. Beesabathuni, M. Kim, Q. Tian, P. Shah, L. Scampavia, T. Spicer, C.-i. Hwang

This study identifies BET inhibition as a potential therapy for BRCA2-deficient pancreatic cancer by showing it enhances autophagy-dependent cell death in these cells.

bioRxiv · May 30, 2023 · PreprintCancer Biology

Identification of Potent Small Molecule Inhibitors of SARS-CoV-2 Entry

S. Jablonski, H. Mou, Y. Otsuka, J. Jablonski, R. S. Adcock, L. Batra, D. Chung, C. Rood, I. M. de Vera, R. Rahaim, S. Ullah, X. Yu, T.-T. Nguyen, M. V. Hull, E. Chen, , T. Spicer

This study identifies small molecule inhibitors of SARS-CoV-2 entry through high-throughput screening and validates Calpeptin as a potent inhibitor of SARS-CoV-2 and some variants.

bioRxiv · Aug 5, 2021Microbiology

Development and pilot screen of novel high content assay for down regulators of expression of heterogenous nuclear ribonuclear protein H2

J. Diez, S. Rajendrarao, S. Baajour, P. Sripadhan, T. Spicer, L. Scampavia, D. Minond

The paper develops a high-content screening assay to identify down regulators of hnRNPH2 for melanoma therapy, finding a 0.5% hit rate in a drug library with two validated compounds.

bioRxiv · Oct 5, 2020 · PreprintCancer Biology

An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer

C.-H. Pan, Y. Otsuka, B. Sridharan, M. Woo, S. Babu, C. V. Leiton, J. D. Bai, D. K. Chang, A. Biankin, L. Scampavia, T. Spicer, L. F. Escobar-Hoyos, K. R. Shroyer

This study identifies K17 as a biomarker for PDAC and shows that PPT, a microtubule inhibitor, is more effective against K17-expressing PDAC cells when combined with Gemcitabine.

bioRxiv · Oct 11, 2019Cancer Biology